The Motley Fool
21 Jun 2026, 22:05 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Grail's Galleri MCED test missed the primary endpoint of demonstrating a statistically significant reduction in Stage III-IV cancers in its NHS-Galleri trial. — Missing a primary endpoint in a landmark trial is a major fundamental setback that typically reduces the probability of regulatory approval and market adoption.
-0.80Grail is currently engaged in an iterative process with the FDA to secure approval for the Galleri test despite the missed trial endpoint. — Continued engagement with the FDA suggests a path to approval still exists, providing a potential catalyst for a stock recovery.
+0.40Management believes upcoming 12-month follow-up data from the NHS trial may eventually prove the test's efficacy as more cancers emerge in the control group. — Positive follow-up data would mitigate the impact of the initial miss and improve the prospects for insurance coverage.
+0.30Continue reading
6 related stories
Search tags
The NHS trial showed a favorable trend toward fewer Stage III-IV cancers specifically within a pre-specified group of 12 deadly cancers. — Success in a high-severity subset of cancers provides a partial proof-of-concept that could support a narrower regulatory label.
+0.20Which stocks this story touches
The company missed a primary endpoint in a landmark trial and seen significant stock decline, despite some recovery and potential for future FDA approval.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
MarketBeat
10h ago
